Walleye Trading
BBIO icon

Walleye Trading’s BridgeBio Pharma BBIO Stock Holding History

Walleye Trading’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$124K Sell
1,659
-86
-5% -$6.02K ﹤0.01% 3332
2026
Q1 		$130K Sell
1,745
-2,386
-58% -$173K ﹤0.01% 3336
2025
Q4 		$316K Buy
4,131
+1,011
+32% +$66.4K ﹤0.01% 3120
2025
Q3 		$162K Sell
3,120
-912
-23% -$44.5K ﹤0.01% 3473
2025
Q2 		$174K Buy
4,032
+3,798
+1,623% +$138K ﹤0.01% 3320
2025
Q1 		$8.09K Sell
234
-9,128
-98% -$308K ﹤0.01% 3863
2024
Q4 		$257K Buy
+9,362
New +$242K ﹤0.01% 3099
2023
Q3 		– Sell
-28,413
Closed -$806K – 4994
2023
Q2 		$489K Buy
+28,413
New +$428K ﹤0.01% 2766
2022
Q3 		– Sell
-26,896
Closed -$244K – 5039
2022
Q2 		$244K Buy
26,896
+13,395
+99% +$112K ﹤0.01% 3541
2022
Q1 		$137K Buy
+13,501
New +$139K ﹤0.01% 4075
2021
Q3 		– Sell
-94
Closed -$6K – 5217
2021
Q2 		$6K Sell
94
-1,248
-93% -$71.3K ﹤0.01% 4989
2021
Q1 		$83K Buy
+1,342
New +$87.8K ﹤0.01% 4172

Other funds holding BBIO

JT
Jupiter Topco New York $245B AUM
KKRC
Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
ACM
Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

Walleye Trading's BBIO Position: Q2 2026 in Review

Walleye Trading reduced its BridgeBio Pharma (BBIO) stake by 4.9% in Q2 2026, selling an estimated $6.02K and leaving 1,659 shares worth $124K. The position accounts for ﹤0.01% of the portfolio, ranked #3332.

Walleye Trading first reported a position in BBIO in Q1 2021 and has held it in 12 quarters since. The position peaked at $489K in Q2 2023. 475 funds tracked by Wall St. Rank hold BBIO as of Q2 2026.

  • Walleye Trading held 1,659 shares of BridgeBio Pharma worth $124K as of Q2 2026.
  • Walleye Trading sold 86 BridgeBio Pharma shares in Q2 2026, an estimated $6.02K.
  • BridgeBio Pharma made up ﹤0.01% of Walleye Trading's portfolio in Q2 2026, its #3332 holding.
  • Walleye Trading first reported a position in BridgeBio Pharma in Q1 2021 and has held it in 12 quarters since.
  • Walleye Trading's BridgeBio Pharma position peaked at $489K in Q2 2023.
  • 475 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2026.

Based on Walleye Trading's 13F filing for Q2 2026, filed 3 Aug 2026.